MitoQ and Exercise Effects on Vascular Health

Last updated: March 24, 2025
Sponsor: University of Colorado, Denver
Overall Status: Active - Not Recruiting

Phase

1

Condition

Menopause

Aging

Treatment

Placebo

MitoQ

Aerobic exercise

Clinical Study ID

NCT05686967
22-1521
R56AG072094
  • Ages 50-120
  • Female
  • Accepts Healthy Volunteers

Study Summary

An impairment in vascular function can lead to the development of age-associated cardiovascular disease (CVD), the leading cause of death in postmenopausal women. Regular aerobic exercise (AE) benefits vascular function in older men by reducing oxidative stress, however, similar AE training improvements are diminished or absent in postmenopausal women. not using estrogen-based hormone therapy. Vascular function and oxidative stress are improved with AE training in postmenopausal women treated with E2, suggesting an essential role of E2 in vascular adaptations to AE in women. Clinical use of E2 is contraindicated for this purpose, thus establishing alternative pharmacological approaches that could be administered as a substitute for E2 to improve AE signaling for vascular benefits and reducing CVD risk in E2-deficient postmenopausal women is biomedically important. The mitochondrial-targeted antioxidant MitoQ may be an alternative to E2 for restoring AE benefits in E2-deficient postmenopausal women given its recently established effectiveness for reducing oxidative stress and improving vascular function in that population. Accordingly, the overall aim of this application is to assess the efficacy of a 12-week randomized controlled trial of moderate intensity AE training combined with oral MitoQ (20 mg/d) compared to AE+oral placebo (PL) or No AE+MitoQ on vascular vasodilatory function (brachial artery flow-mediated dilation; FMD) in healthy E2-deficient postmenopausal women. Insight into the causes for the improvement related to molecules (e.g., nitric oxide) that promote vasodilation, mitochondrial function, oxidative stress, and the influence of "circulating factors" will also be obtained. We hypothesize that AE+MitoQ will improve both FMD > AE+PL and > No AE+MitoQ, and that No AE+MitoQ will improve FMD > AE+PL. The greater improvements in endothelial function with AE+MitoQ vs. both AE+PL and No AE+MitoQ, and with No AE+MitoQ vs. AE+PL will be mediated by greater improvements in nitric oxide production, mitochondrial function, and mitochondrial and oxidative stress linked, at least in part, to changes in "circulating factors". The expected results from this study will establish the efficacy of MitoQ for restoring AE-vascular signaling in E2-deficient postmenopausal women and will provide the foundation for development of evidence-based guidelines for sex-specific AE programs for improving vascular health and preventing CVD in postmenopausal women.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • resting blood pressure <140/90 mmHg;

  • fasted glucose <126 mg/dL;

  • sedentary/recreationally active (<2 days/wk vigorous exercise);

  • healthy, as determined by medical history, physical examination, standard bloodchemistries (chemistry panel, CBC and circulating thyroid levels) and ECG at restand during exercise;

  • nonsmokers;

  • no use of medications that might influence cardiovascular function (i.e.,antihypertensive, lipid lowering medications, blood thinners);

  • no use of vitamin supplements or anti-inflammatory medications, or willing to stop 1month prior to enrollment and for the duration of the study;

  • no use of HT for at least 6 months;

  • body mass index <40kg/m2.

Exclusion

Exclusion Criteria:

  • Volunteers will be excluded from the study if they have contraindications to MitoQor AE.

  • acute liver disease, history of venous thromboembolic events, preexisting or activecardiac, renal or hepatic disease, history of stomach ulcer or bleeding or epilepsyor other seizure disorder;

  • diabetes, active infection, disease that affects the nervous system,

  • an abnormal resting ECG, angina and/or ECG evidence of acute myocardial ischemiaduring the exercise test (development of ST-segment depression of more than 0.3 mVthat is either horizontal, down-sloping, or slowly upsloping -less than 1 mvolt/secand lasts more than 0.08 sec; ST elevation; chest pain or discomfort), bundle branchblocks, A-V block greater than first degree, arrhythmias;

  • chronic infections;

  • thyroid dysfunction, defined as an ultrasensitive TSH <0.5 or >5.0 mU/L; volunteerswith abnormal TSH values will be re-considered for participation in the study afterfollow-up evaluation by the PCP with initiation or adjustment of thyroid hormonereplacement;

  • orthopedic or other problems that would interfere with participation in the exerciseprogram

The volunteers who choose to participate will do so with the understanding that they will be randomly assigned to study groups that involve either AE+PL (33% chance), No AE+MitoQ (33% chance) or AE+MitoQ (33% chance).

Study Design

Total Participants: 22
Treatment Group(s): 3
Primary Treatment: Placebo
Phase: 1
Study Start date:
January 16, 2023
Estimated Completion Date:
November 30, 2025

Connect with a study center

  • University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research Laboratory

    Aurora, Colorado 80045
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.